US11090294 — Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Method of Use · Assigned to Glaxo Group Ltd · Expires 2030-11-29 · 5y remaining
What this patent protects
This patent provides combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist for inhaled administration via the nose or mouth.
USPTO Abstract
Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
Drugs covered by this patent
- Arnuity Ellipta (FLUTICASONE FUROATE) · Haleon Us Holdings
- umeclidinium-bromide (UMECLIDINIUM BROMIDE)
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3202 |
— | Arnuity Ellipta |
U-3203 |
— | umeclidinium-bromide |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.